<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRP</journal-id><journal-title-group><journal-title>Asian Case Reports in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2328-045X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRP.2018.64006</article-id><article-id pub-id-type="publisher-id">ACRP-28068</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRP20180400000_89072201.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  整合素α4在难治复发急性淋巴细胞白血病中的研究进展
  Research Advances of Integrin Alpha 4 in Drug Resistant or Relapsed Acute Lymphoblastic Leukemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>倚琪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>学东</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>阮</surname><given-names>永胜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南方医科大学南方医院儿科，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>18</day><month>12</month><year>2018</year></pub-date><volume>06</volume><issue>04</issue><fpage>35</fpage><lpage>39</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    当下难治复发急性淋巴细胞白血病(ALL)不管在成人还是儿童中均面临着较差预后的治疗挑战，而整合素α4基本表达于所有淋巴细胞表面，且是参与细胞粘附介导耐药(CAM-DR)机制中重要组成部分，故本文将从CAM-DR在难治复发ALL中的作用、整合素α4介导的CAM-DR效应、拮抗整合素α4在治疗难治复发ALL的意义三方面展开综述，为治疗难治复发ALL病人提供一种新的治疗思路。
    Chemotherapeutic drug resistance or relapse in acute lymphoblastic leukemia (r/r ALL) is a chal-lenging problem, resulting in poor prognosis. Integrin alpha 4 plays a critical role in mechanism of cell adhesion-mediated drug resistance (CAM-DR), while expressing on most leukocyte surface broadly including lymphoblastic leukemia cell. We here review the mechanism of CAM-DR in r/r ALL, the role of integrin alpha 4 in mechanism of CAM-DR and the targeting of integrin alpha 4 as a novel strategy for treatment of r/r ALL. 
  
 
</p></abstract><kwd-group><kwd>整合素α4，急性淋巴细胞白血病，细胞粘附介导的药物耐药性, Integrin Alpha 4</kwd><kwd> Acute Lymphoblastic Leukemia</kwd><kwd> Cell Adhesion-Mediated Drug Resistance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>整合素α4在难治复发急性淋巴细胞白血病中的研究进展<sup> </sup></title><p>徐倚琪，吴学东<sup>*</sup>，阮永胜<sup>*</sup></p><p>南方医科大学南方医院儿科，广东 广州</p><p><img src="//html.hanspub.org/file/1-2460086x1_hanspub.png" /></p><p>收稿日期：2018年11月26日；录用日期：2018年12月11日；发布日期：2018年12月18日</p><disp-formula id="hanspub.28068-formula13"><graphic xlink:href="//html.hanspub.org/file/1-2460086x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>当下难治复发急性淋巴细胞白血病(ALL)不管在成人还是儿童中均面临着较差预后的治疗挑战，而整合素α4基本表达于所有淋巴细胞表面，且是参与细胞粘附介导耐药(CAM-DR)机制中重要组成部分，故本文将从CAM-DR在难治复发ALL中的作用、整合素α4介导的CAM-DR效应、拮抗整合素α4在治疗难治复发ALL的意义三方面展开综述，为治疗难治复发ALL病人提供一种新的治疗思路。</p><p>关键词 :整合素α4，急性淋巴细胞白血病，细胞粘附介导的药物耐药性</p><disp-formula id="hanspub.28068-formula14"><graphic xlink:href="//html.hanspub.org/file/1-2460086x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2460086x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2460086x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>急性淋巴细胞白血病(Acute Lymphoblastic Leukemia, ALL)是源于B或T祖细胞异常增生的高度恶性血液病，化疗是其治疗的主要手段。在近20年内，儿童ALL的5年总体生存率(OS)得到了显著的提升，超过了80%，但成人的ALL患者预后则相对较差，仅有50%左右 [<xref ref-type="bibr" rid="hanspub.28068-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.28068-ref2">2</xref>] 。据报道，我国儿童高危ALL组5年无事件生存率(EFS)仅在62% [<xref ref-type="bibr" rid="hanspub.28068-ref3">3</xref>] 。由于化疗耐药和复发的机制尚未明确，故化疗耐药和复发成为当代ALL治疗上的首要难题，目前仍有将近20%儿童ALL以及过半的成人ALL患者面临化疗耐药和复发的困境 [<xref ref-type="bibr" rid="hanspub.28068-ref4">4</xref>] 。通过抑制或阻断难治或复发ALL中整合素α4表达以期消除细胞粘附介导的药物耐药性(Cell Adhesion-Mediated Drug Resistance, CAM-DR)是目前新兴热点研究学说之一。</p></sec><sec id="s4"><title>2. CAM-DR在难治复发ALL中的作用</title><sec id="s4_1"><title>2.1. 白血病初始细胞与骨髓微环境</title><p>白血病初始细胞(Leukemia Initiating Cells, LICs)与正常造血干细胞(Hematopoietic Stem Cells, HSCs)有许多相似的地方。大多数LICs处于静止期，因此可以躲避针对细胞周期化疗药物的杀伤，此外，LICs具有自我更新和形成分化更多的LICs潜力 [<xref ref-type="bibr" rid="hanspub.28068-ref5">5</xref>] 。1978年，Schofield首次提出了健康HSCs居住在骨髓龛内的骨髓微环境假说，骨髓龛具有免于环境压力和强力支持HSCs维持自我更新及多系分化能力 [<xref ref-type="bibr" rid="hanspub.28068-ref6">6</xref>] 。骨髓龛分为成骨细胞龛和血管龛两类，前者位于骨内膜内由成骨细胞、破骨细胞、施万细胞和调节T细胞组成，后者位于血管窦壁上由CXC趋化因子12-富含网状细胞(CAR)、内皮细胞、间充质基质细胞(MSCs)和血管周基质细胞组成 [<xref ref-type="bibr" rid="hanspub.28068-ref7">7</xref>] 。通过大量的细胞因子、趋化因子和粘附分子发挥调节HSC的作用。由于LICs通过相应的信号传导可以占据正常骨髓龛形成骨髓白血病龛，从而躲避化疗药物诱导死亡，形成微小残留病灶(MRD)，产生化疗耐药，同时具有自我复制增殖潜力，导致复发 [<xref ref-type="bibr" rid="hanspub.28068-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.28068-ref8">8</xref>] 。</p></sec><sec id="s4_2"><title>2.2. CAM-DR</title><p>CAM-DR是指造血肿瘤细胞使得借助整合素和其他趋化因子等通过粘附于骨髓微环境中的基质细胞转化成多药耐药表型 [<xref ref-type="bibr" rid="hanspub.28068-ref9">9</xref>] 。CAM-DR该机制普遍存在于白血病、淋巴瘤、多发性骨髓瘤等血液系统恶性肿瘤，且耐药谱较其他耐药机制更广，在结构及功能上能抑制相当广泛DNA损伤药物所诱导的凋亡作用。经典的耐药机制是由于细胞内药物泵出增多致细胞内药物的蓄积浓度降低所致。</p></sec><sec id="s4_3"><title>2.3. 难治复发ALL耐药机制</title><p>骨髓是ALL最常见的复发部位，且有研究证实骨髓龛中整合素α4介导粘附作用是其重要CAM-DR作用机制之一 [<xref ref-type="bibr" rid="hanspub.28068-ref10">10</xref>] 。Mudry等通过对1种T-ALL和3种pre-B-ALL细胞株与骨髓基质细胞共培养的体外研究发现，ALL细胞能主动与骨髓基质细胞接触，并且骨髓基质细胞能促进在有化疗药依托泊苷或阿糖胞苷环境下ALL的增殖 [<xref ref-type="bibr" rid="hanspub.28068-ref11">11</xref>] ，其中促进ALL生存的重要作用是通过介导血管细胞粘附分子-1 (VCAM-1)发生的。</p></sec></sec><sec id="s5"><title>3. 整合素α4介导CAM-DR中的作用</title><sec id="s5_1"><title>3.1. 整合素α4及配体</title><p>整合素(Integrin)是由18种α链和8种β链组成的细胞表面24种不同的异二聚体糖蛋白 [<xref ref-type="bibr" rid="hanspub.28068-ref12">12</xref>] 。分为细胞内部分和细胞外部分，具有传递细胞信号通路和粘连作用。其中整合素α4β1又称很晚期抗原4 (Very Late Antigen-4, VLA4)，主要表达于所有的浆细胞、正常淋巴细胞和造血祖细胞，其配体是I型膜蛋白血管细胞粘附分子-1 (Vascular Cell Adhesion Molecule-1, VCAM-1)。VCAM-1主要表达于血管内皮细胞和骨髓基质细胞中。</p></sec><sec id="s5_2"><title>3.2. 整合素α4作用</title><sec id="s5_2_1"><title>3.2.1. 细胞内信号传导激活生存、增殖通路</title><p>整合素可以通过与相应受体结合直接或间接介导细胞内信号通路 [<xref ref-type="bibr" rid="hanspub.28068-ref13">13</xref>] 。间接信号通路是通过整合素与其受体酪氨酸激酶(tyrosine kinase, RTK)形成复合体而产生 [<xref ref-type="bibr" rid="hanspub.28068-ref14">14</xref>] 。而直接信号通路是通过整合素连接激酶(integrin-linked kinase, ILK)与整合素结合产生。ILK激活是依附于磷脂酰肌醇-3-羟激酶(PI3K)/AKT [<xref ref-type="bibr" rid="hanspub.28068-ref15">15</xref>] 。Tabe等人提出ILK/Akt通路是对白血病细胞存活至关重要的信号通路 [<xref ref-type="bibr" rid="hanspub.28068-ref16">16</xref>] 。</p><p>细胞内的直接信号的激活是通过整合素和多个酪氨酸激酶磷酸化产生。焦点粘附激酶(focal adhesion kinase, FAK)酪氨酸磷酸化后通过两条信号通路激活细胞外信号调节激酶(extracellular signal regulated kinase, ERK)和丝裂原活化蛋白激酶(mitogen-activated protein kinase, MAPK) [<xref ref-type="bibr" rid="hanspub.28068-ref15">15</xref>] 。第一条通路，FAK可以通过CrK来补充C3G和RAP1，来诱导B-Raf活性和ERK及MAPK的激活。第二条通路包括生长因子受体-2 (growth-factor-receptorbound-2, GRB2)和交换因子(son-of-sevenless, SOS)复合物，它可以激活Ras-ERK/MAPK。α亚基通过 SFK耦合也能激活ERK/MAPK，从而激活GRB2-SOS复合体和Ras下游的ERK/MAPK信号。</p></sec><sec id="s5_2_2"><title>3.2.2. 细胞外粘连保护</title><p>整合素α4细胞外部分主要是介导细胞粘连作用。细胞质域连接信号与细胞骨架相连。细胞质尾部与信号适配器桩蛋白结合 [<xref ref-type="bibr" rid="hanspub.28068-ref12">12</xref>] 。Lim等人证明了α4细胞质域是一种I型PKA特异性的a激酶锚蛋白(a-kinase anchoring proteins，AKAP) [<xref ref-type="bibr" rid="hanspub.28068-ref17">17</xref>] 。Rivera Rosado等人已经指出细胞质的α4尾部可独立于桩蛋白与非肌球蛋白IIA (myosin IIA)结合，指出了关于整合素与肌动蛋白细胞骨架关联和整合素调节细胞迁徙新的机制 [<xref ref-type="bibr" rid="hanspub.28068-ref18">18</xref>] 。</p></sec><sec id="s5_2_3"><title>3.2.3. 整合素α4骨髓基质细胞相互作用介导白血病细胞生存和抵抗化疗</title><p>研究观察发现骨髓基质细胞可以激活pre-B ALL细胞整合素β1从而抑制capase-3和7的活性，且在pre-B ALL与骨髓基质细胞共培养后接受化疗，发现促凋亡的23kDa Bcl-2蛋白表达明显减少 [<xref ref-type="bibr" rid="hanspub.28068-ref19">19</xref>] 。Wang等指出ALL细胞化疗后PARP和Bcl-2水平降低是Akt介导的，证实了PI3K/Akt旁路是基质细胞介导化疗保护及白血病细胞生存的关键旁路 [<xref ref-type="bibr" rid="hanspub.28068-ref20">20</xref>] 。</p><p>最近，有文献指出B-ALL与骨髓来源间充质细胞是通过Notch-3和-4细胞通路进行反应 [<xref ref-type="bibr" rid="hanspub.28068-ref21">21</xref>] 。Bertrand通过抑制mTOR或PI3K/MEK信号通路可以使B-ALL细胞株BLIN-2导致快速凋亡 [<xref ref-type="bibr" rid="hanspub.28068-ref22">22</xref>] 。</p><p>Andreeff指出白血病细胞和骨髓基质细胞之间可能是通过VCAM-1/VLA4进行信号传导从而激活NF-κB信号通路发挥CAM-DR骨髓基质细胞对白血病细胞化疗耐药作用 [<xref ref-type="bibr" rid="hanspub.28068-ref23">23</xref>] 。</p></sec></sec></sec><sec id="s6"><title>4. 拮抗整合素α4药物在难治性ALL治疗中的意义</title><p>当下许多医药公司正迅速的开发出用于不同疾病的拮抗不同类型的整合素药物，并展开相应的临床前期研究和临床研究。</p><p>现已有超过260种拮抗整合素药物正在临床评估中，但只有少数药物被批准应用于临床。其中一种是靶向于α4β1和α4β7的单克隆抗体那他珠单抗(Natalizumab)，这是现在唯一一个运用在临床上的整合素α4靶向药物，用于治疗复发难治的多发性硬化病和难治性炎性肠病，该药具有很高的有效性、安全性和耐受性 [<xref ref-type="bibr" rid="hanspub.28068-ref24">24</xref>] 。有研究发现，对复发难治pre-B ALL的NSG小鼠模型进行长春新碱、地塞米松、左旋门冬酰胺酶化疗加上那他珠单抗组较单纯化疗组显著延长小鼠的生存时间(p &lt; 0.0001) [<xref ref-type="bibr" rid="hanspub.28068-ref25">25</xref>] 。然而，那他珠单抗最常见严重的并发症是出现进展性多灶性脑白质病(Progressive multifocal leukoencephalopathy，PML)限制了其在临床上的应用 [<xref ref-type="bibr" rid="hanspub.28068-ref26">26</xref>] 。</p><p>尚在临床前期研究中的小分子整合素α4拮抗剂主要有两种类型，分别是基于尿素类的和基于苯丙氨酸类的。基于苯丙氨酸类代表的拮抗剂有AJM300、 SB683699 (Firategrast，非拉司特)、R-411 (Valategrast，伐拉斯特)和CDP323。这些苯丙氨酸衍生的新化合物是通过形成环肽来增强对整合素α4的拮抗效力。基于尿素类代表的拮抗剂包括Bio-1211，Bio5192，IVL745和TBC3486 [<xref ref-type="bibr" rid="hanspub.28068-ref27">27</xref>] 。</p><p>其中TBC3486 [<xref ref-type="bibr" rid="hanspub.28068-ref28">28</xref>] 和AVA4746 [<xref ref-type="bibr" rid="hanspub.28068-ref29">29</xref>] 均是VCAM-1的高模仿小分子制剂，可竞争性抑制整合素α4与VCAM-1结合，从而发挥拮抗整合素α4作用。Hsieh YT和Ruan Y发现使用TBC3486或AVA4746同样可以使得复发难治前B-ALL小鼠在化疗中明显获益，使用整合素α4拮抗剂联合化疗组生存时间明显长于单纯化疗组，并在体外研究发现其具有去粘附于VCAM-1的作用。</p><p>综上，整合素α4在复发难治ALL细胞表面广泛表达，通过拮抗整合素α4可以使得复发难治ALL细胞特别是LIC脱离骨髓基质细胞CAM-DR介导的化疗保护作用，从而可以通过经典化疗、药物或生物靶向治疗彻底清除LIC。由此可见整合素α4拮抗剂在ALL中有着良好的应用前景，并为难治复发ALL病人提供了新的治疗思路。</p></sec><sec id="s7"><title>基金项目</title><p>南方医科大学留学回国培育项目LX2017N005。</p></sec><sec id="s8"><title>文章引用</title><p>徐倚琪,吴学东,阮永胜. 整合素α4在难治复发急性淋巴细胞白血病中的研究进展Research Advances of Integrin Alpha 4 in Drug Resistant or Relapsed Acute Lymphoblastic Leukemia[J]. 亚洲儿科病例研究, 2018, 06(04): 35-39. https://doi.org/10.12677/ACRP.2018.64006</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28068-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Pui, C.H., Mullighan, C.G., Evans, W.E., et al. (2012) Pediatric Acute Lymphoblastic Leukemia: Where Are We Going and How Do We Get There? Blood, 120, 1165-1174. https://doi.org/10.1182/blood-2012-05-378943</mixed-citation></ref><ref id="hanspub.28068-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Parikh, S.A. and Litzow, M.R. (2014) Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Therapies under Development. Future Oncology, 10, 2201-2212. https://doi.org/10.2217/fon.14.81</mixed-citation></ref><ref id="hanspub.28068-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">阮永胜, 吴学东, 冯晓勤, 等. ALL-BFM95方案治疗儿童急性淋巴细胞白血病高危患儿的预后分析[J]. 中国当代儿科杂志, 2015(4): 327-331.</mixed-citation></ref><ref id="hanspub.28068-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">阮永胜, 吴学东. 儿童急性淋巴细胞白血病复发的研究进展[J]. 中华临床医师杂志(电子版), 2014(18): 3359-3363.</mixed-citation></ref><ref id="hanspub.28068-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Fragoso, R. and Barata, J.T. (2014) PTEN and Leukemia Stem Cells. Advances in Biological Regulation, 56, 22-29.  
https://doi.org/10.1016/j.jbior.2014.05.005</mixed-citation></ref><ref id="hanspub.28068-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Schofield, R. (1978) The Relationship between the Spleen Colo-ny-Forming Cell and the Haemopoietic Stem Cell. Blood Cells, 4, 7-25.</mixed-citation></ref><ref id="hanspub.28068-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tabe, T. and Konopleva, M. (2014) Advances in Understanding the Leukaemia Microenvironment. British Journal of Haematology, 164, 767-778. https://doi.org/10.1111/bjh.12725</mixed-citation></ref><ref id="hanspub.28068-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Colmone, A., Amorim, M., Pontier, A.L., et al. (2008) Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells. Science, 322, 1861-1865. https://doi.org/10.1126/science.1164390</mixed-citation></ref><ref id="hanspub.28068-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hazlehurst, L.A., Argilagos, R.F. and Dalton, W.S. (2007) Beta1 Integrin Mediated Adhesion Increases Bim Protein Degradation and Contributes to Drug Resistance in Leukaemia Cells. British Journal of Haematology, 136, 269-275.  
https://doi.org/10.1111/j.1365-2141.2006.06435.x</mixed-citation></ref><ref id="hanspub.28068-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">陈幸华, 高蕾, 张曦, 等. 新型白血病骨髓基质细胞黏附介导耐药模型构建的探索性研究[J]. 中华医学杂志, 2007, 87(20): 1380-1383.</mixed-citation></ref><ref id="hanspub.28068-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Mudry, R.E., Fortney, J.E., York, T., et al. (2000) Stromal Cells Regulate Survival of B-Lineage Leukemic Cells during Chemotherapy. Blood, 96, 1926-1932.</mixed-citation></ref><ref id="hanspub.28068-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Hynes, R.O. (2002) Integrins: Bidirectional, Allosteric Signaling Machines. Cell, 110, 673-687.  
https://doi.org/10.1016/S0092-8674(02)00971-6</mixed-citation></ref><ref id="hanspub.28068-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Streuli, C.H. and Akhtar, N. (2009) Signal Co-Operation between Integrins and Other Receptor Systems. Biochemical Journal, 418, 491-506. https://doi.org/10.1042/BJ20081948</mixed-citation></ref><ref id="hanspub.28068-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cabodi, S., Moro, L., Bergatto, E., et al. (2004) Integrin Regulation of Epi-dermal Growth Factor (EGF) Receptor and of EGF-Dependent Responses. Biochemical Society Transactions, 32, 438-442. https://doi.org/10.1042/bst0320438</mixed-citation></ref><ref id="hanspub.28068-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Guo, W. and Giancotti, F.G. (2004) Integrin Signalling during Tumour Pro-gression. Nature Reviews Molecular Cell Biology, 5, 816-826. https://doi.org/10.1038/nrm1490</mixed-citation></ref><ref id="hanspub.28068-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Tabe, Y., Jin, L., Tsutsumi-Ishii, Y., et al. (2007) Activation of Integrin-Linked Kinase Is a Critical Prosurvival Pathway Induced in Leukemic Cells by Bone Marrow-Derived Stromal Cells. Cancer Research, 67, 684-694.  
https://doi.org/10.1158/0008-5472.CAN-06-3166</mixed-citation></ref><ref id="hanspub.28068-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lim, C.J., Han, J., Yousefi, N., et al. (2007) Alpha4 Integrins Are Type I cAMP-Dependent Protein Kinase-Anchoring Proteins. Nature Cell Biology, 9, 415-421. https://doi.org/10.1038/ncb1561</mixed-citation></ref><ref id="hanspub.28068-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Rivera Rosado, L.A., Horn, T.A., McGrath, S.C., et al. (2011) Association be-tween alpha4 Integrin Cytoplasmic Tail and Non-Muscle Myosin IIA Regulates Cell Migration. Journal of Cell Science, 124, 483-492.  
https://doi.org/10.1242/jcs.074211</mixed-citation></ref><ref id="hanspub.28068-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Fortney, J.E., Hall, B.M., Bartrug, L., et al. (2002) Chemotherapy Induces bcl-2 Cleavage in Lymphoid Leukemic Cell Lines. Leuk Lymphoma, 43, 2171-2178. https://doi.org/10.1080/1042819021000033024</mixed-citation></ref><ref id="hanspub.28068-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Fortney, J.E. and Gibson, L.F. (2004) Stromal Cell Protection of B-Lineage Acute Lymphoblastic Leukemic Cells during Chemotherapy Requires Active Akt. Leukemia Research, 28, 733-742.  
https://doi.org/10.1016/j.leukres.2003.10.033</mixed-citation></ref><ref id="hanspub.28068-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Nwabo Kamdje, A.H. and Krampera, M. (2011) Notch Signaling in Acute Lymphoblastic Leukemia: Any Role for Stromal Microenvironment? Blood, 118, 6506-6514. https://doi.org/10.1182/blood-2011-08-376061</mixed-citation></ref><ref id="hanspub.28068-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bertrand, F.E., Spengemen, J.D., Shelton, J.G., et al. (2005) Inhi-bition of PI3K, mTOR and MEK Signaling Pathways Promotes Rapid Apoptosis in B-Lineage ALL in the Presence of Stromal Cell Support. Leukemia, 19, 98-102.  
https://doi.org/10.1038/sj.leu.2403560</mixed-citation></ref><ref id="hanspub.28068-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Jacamo, R., Chen, Y., Wang, Z., et al. (2014) Reciprocal Leukemia-Stroma VCAM-1/VLA-4-Dependent Activation of NF-kB Mediates Chemoresistance. Blood, 123, 2691-2702. https://doi.org/10.1182/blood-2013-06-511527</mixed-citation></ref><ref id="hanspub.28068-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Y., Schurpf, T. and Springer, T.A. (2013) How Natalizumab Binds and Antagonizes alpha4 Integrins. The Journal of Biological Chemistry, 288, 32314-32325. https://doi.org/10.1074/jbc.M113.501668</mixed-citation></ref><ref id="hanspub.28068-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Hsieh, Y.T., Gang, E.J., Geng, H., et al. (2013) Integrin alpha4 Blockade Sensitizes Drug Resistant pre-B Acute Lymphoblastic Leukemia to Chemotherapy. Blood, 121, 1814-1818. https://doi.org/10.1182/blood-2012-01-406272</mixed-citation></ref><ref id="hanspub.28068-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Schwab, N., Schneider-Hohendorf, T., Melzer, N., et al. (2017) Natalizumab-Associated PML Challenges with Incidence, Resulting Risk, and Risk Stratification. Neurology, 88, 1197-1205.  
https://doi.org/10.1212/WNL.0000000000003739</mixed-citation></ref><ref id="hanspub.28068-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Shishido, S., Bönig, H. and Kim, Y.M. (2014) Role of Integrin Alpha4 in Drug Resistance of Leukemia. Frontiers in Oncology, 4, 99. https://doi.org/10.3389/fonc.2014.00099</mixed-citation></ref><ref id="hanspub.28068-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Hsieh, Y.T., Gang, E.J. and Shishido, S.N. (2014) Effects of the Small-Molecule Inhibitor of Integrin A4, TBC3486, on Pre-B-ALL Cells. Leukemia, 28, 2101-2104. https://doi.org/10.1038/leu.2014.182</mixed-citation></ref><ref id="hanspub.28068-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ruan, Y., Gang, E.J., Kim, H.N., et al. (2016) AVA4746, an Orally Available, Clinical Grade Antagonist of Integrin Alpha 4, Sensitizes Pre-B Cell Acute Lymphoblastic Leukemia to Chemotherapy. Blood, 128, 2765.</mixed-citation></ref></ref-list></back></article>